Smith & Nephew casts off DermaGraft while orthopaedics still stands strong
This article was originally published in Clinica
Smith & Nephew is packing up its DermaGraft business after the US FDA unexpectedly refused to approve the woundcare product for treatment of venous leg ulcers.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.